FDA’s Office of Compliance Releases 2021 Annual Report

Article

FDA’s Office of Compliance has released its 2021 Annual Report, which highlights the agency’s successes in public health.

The Office of Compliance in FDA’s Center for Drug Evaluation and Research has released the office’s 2021 Annual Report. The report focuses on the various successes of the agency in public health throughout 2021.

The report highlights key initiatives that had a direct impact on patient safety, including efforts to address the COVID-19 pandemic. Other areas of focus include addressing the opioid crisis, compounded drug quality, drug supply chain security, fraudulent and unsafe drugs, amongst others throughout 2021.

The Office of Compliance’s efforts regarding COVID-19 included shielding patients and consumers from unsafe, ineffective, and poor-quality drugs, including unsafe hand sanitizers and products fraudulently claiming to prevent, treat, or cure COVID-19. The office also took action to increase access to critical medicines used to treat patients with COVID-19, such as albuterol, oxygen, and propofol, as well as support the development of new therapeutics.

The use of alternative tools used when on-site inspections were prevented due to COVID-19 was also described in the report, focusing on reorganization to strengthen oversight of drug compounding and prevention of fraudulent, poor quality, and unsafe drugs. The Office of Compliance makes strategic and risk-based decisions that are guided by law and science to foster global collaboration, promote voluntary compliance, and take decisive and swift actions to protect patients.

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes